Biomea Fusion To Host Conference Call And Webcast On Wednesday, October 30 At 4:30 Pm ET To Announce Lead Clinical Candidate, BMF-650, A Oral Small-Molecule GLP-1 Receptor Agonist And Preclinical Data Combining BMF-219 With A GLP-1 RA-Based Therapy
Arcadium Lithium, Norwegian Cruise Line, GitLab, Chewy And Other Big Stocks Moving Higher On Wednesday
Biomea Fusion Analyst Ratings
Biomea Fusion Initiated With a Buy at EF Hutton
Biomea Fusion To Present Data From The Company's COVALENT-111 and COVALENT-112 Diabetes Clinical Trials Will Be Featured During A Long Oral Presentation And Two Short Oral Presentations At The 1st Asian Conference On Innovative Therapies For Diabetes...
Independent Director of Biomea Fusion Michael J. Hitchcock Buys 200% More Shares
